TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23528398
Drug: 5% mexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% mexidol solution
Study: 21647846
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of EMLA (2.5% lidocaine and 2.5% prilocaine)
Study: 18796000
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg/IV within the first 2 weeks and at 3 months after transplantation
Study: 18796000
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose infusions at the same time points)
Study: 18796000
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg/IV
Study: 16774715
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (Control in IS study)
Study: 14992899
Drug: Hypothermic protective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic protective solution
Study: 11698275
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg rabbit ATG (Thymoglobulin)
Study: 11698275
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg rabbit ATG
Study: 9293721
Drug: PRP-T Hib
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T Hib conjugate vaccine
Study: 8282480
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant interferon-alpha (rIFN-alpha) at a dose of 3 x 10(6) units thrice weekly for three months, followed by 1.5 x 10(6) units thrice weekly for the next three months
Study: 27843803
Drug: Duligotuzumab (1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duligotuzumab (1100 mg IV, q2w)
Study: 27843803
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 load, 250 mg/m2 IV, q1w)
Study: 25665116
Drug: FLOSEAL 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOSEAL 5 mL
Study: 25665116
Drug: FLOSEAL 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOSEAL 10 mL
Study: 23046438
Drug: Black currant
Normalized name: Black currant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black currant anthocyanins (BCACs) 50 mg/day
Study: 21966075
Drug: DXP 3
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DXP 3 mg
Study: 21966075
Drug: DXP 6
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DXP 6 mg
Study: 16702703
Drug: Clinical actions
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical actions (e.g., speak positively about treatments, provide encouragement)
Study: 12811019
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized ragweed pollen extract tablets
Study: 12811019
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with highest dose (3 tablets 3 times a week)
Study: 8649658
Drug: 1.25 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mmol/l Ca dialysate
Study: 8649658
Drug: 1.75 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 mmol/l Ca dialysate
Study: 1350803
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 10 mg/ml
Study: 1350803
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 30 mg/ml
Study: 6209080
Drug: Lorcainide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcainide (100 mg/d by mouth, three times daily)
Study: 22398060
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily mesalazine (1×2 g)
Study: 22398060
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily mesalazine (2×1 g)
Study: 15740828
Drug: Intravenous pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentazocine (0.5mg/kg)
Study: 12164994
Drug: Preventive occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive occupational therapy (OT)
Study: 10207539
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg three times a day
Study: 10207539
Drug: Ritonavir 600
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 600 mg twice a day
Study: 10207539
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg twice a day and saquinavir 400 mg twice a day
Study: 10207539
Drug: Indinavir (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (in antiretroviral drug-naive patients)
Study: 10207539
Drug: Ritonavir (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (in antiretroviral drug-naive patients)
Study: 10207539
Drug: Ritonavir +
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir + saquinavir (in antiretroviral drug-naive patients)
Study: 10207539
Drug: Indinavir (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (in drug-experienced patients)
Study: 10207539
Drug: Ritonavir (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (in drug-experienced patients)
Study: 10207539
Drug: Ritonavir +
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir + saquinavir (in drug-experienced patients)
Study: 9097805
Drug: Subconjunctival mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival mitomycin C (0.5 mg/ml) applied for 1-, 3-, or 5-minutes
Study: 2710266
Drug: Intravenous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ranitidine 50 mg
Study: 2710266
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine 150 mg
Study: 47944
Drug: C.F. antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.F. antibodies (IgG)
Study: 31941483
Drug: Intraarticular HADMSCs
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular HADMSCs injection with LIPUS
Study: 31941483
Drug: Intraarticular HADMSCs
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular HADMSCs injection with sham LIPUS
Study: 23881774
Drug: Soy fiber
Normalized name: Soy Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy fiber (SF) biscuits (approximately 100 g/day) for 12 weeks
Study: 21441616
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg daily) for 30 and 90 days
Study: 19624576
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg, maximum 400 mg)
Study: 19624576
Drug: Acetaminophen-codeine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen-codeine (1 mg/kg as codeine, maximum 60 mg)
Study: 17105953
Drug: GHB 40
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 40 mg/kg
Study: 17105953
Drug: GHB 50
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 50 mg/kg
Study: 17105953
Drug: GHB 60
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 60 mg/kg
Study: 17105953
Drug: GHB 72
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 72 mg/kg
Study: 15152747
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K antagonists (e.g., warfarin) for stroke prevention in AF
Study: 12100790
Drug: Computer Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer Assisted Meal Related Insulin Therapy (CAMIT)
Study: 12100790
Drug: Multiple Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Subcutaneous Injection (MSI)
Study: 9166489
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of paclitaxel (135 mg/m2)
Study: 9166489
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of paclitaxel (200 mg/m2)
Study: 9166489
Drug: 3-day divided
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day divided dose schedule of paclitaxel (200 mg/m2)
Study: 9166489
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of paclitaxel (135 mg/m2 and 200 mg/m2)
Study: 9166489
Drug: 200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2 dose of paclitaxel in non-small cell lung cancer
Study: 334211
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg once-daily
Study: 334211
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once-daily
Study: 334211
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg once-daily
Study: 31216226
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus concurrent bevacizumab (15 mg/kg, cycles 2 to 6)
Study: 31216226
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus concurrent and maintenance bevacizumab (cycles 2 to 22)
Study: 31216226
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus concurrent and maintenance bevacizumab (stage IV)
Study: 31216226
Drug: Chemotherapy control
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy control (n = 625)
Study: 27895192
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (including Ca++-channel blockers and diuretics)
Study: 25880685
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus CMC 1% (n = 90)
Study: 25880685
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (control group, n = 90)
Study: 17416480
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum creatinine > 150 μmol/L
Study: 17416480
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum creatinine ≤ 150 μmol/L
Study: 17416480
Drug: Initial route
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial route of CYC administration
Study: 15543358
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy with 0.625 mg of equine conjugated estrogens and 2.5 mg of medroxyprogesterone
Study: 9590593
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% eyedrops (10 times)
Study: 9590593
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% eyedrops (6 times)
Study: 9590593
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (200 mg)
Study: 9590593
Drug: Intravenous ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ofloxacin (200 mg)
Study: 28216244
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (5 doses of 2.7 x 10^5 PfSPZ at days 0, 28, 56, 84, and 140)
Study: 25894892
Drug: β-Alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-Alanine (BA) supplementation (4.0-5.6 g day(-1))
Study: 17087307
Drug: Cell transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell transplantation therapy
Study: 14627786
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg once weekly)
Study: 28573743
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg twice weekly)
Study: 10831972
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg three times daily for 6 months
Study: 10831972
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 3.75 mg depot every 28 days for 6 months
Study: 9356085
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 15 mg/kg before CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Study: 9356085
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 15 mg/kg after CPB, followed by infusion of 1 mg x kg(‐1) x h(‐1) for 5 h
Study: 9356085
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 15 mg/kg before CPB
Study: 9356085
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 15 mg/kg after CPB
Study: 8210561
Drug: Initial steroid
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial steroid pulses 500 mg x3 (n = 17)
Study: 8210561
Drug: Low oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low oral steroid treatment (n = 20)
Study: 8210561
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (n = 3)
Study: 3820944
Drug: Intravenous deferoxamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous deferoxamine, 40 mg/kg
Study: 3820944
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and intraperitoneal deferoxamine
Study: 24746177
Drug: Aprepitant add-on
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant add-on triple antiemetic therapy (with a 5-HT(3) receptor antagonist and dexamethasone)
Study: 24746177
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic therapy (5-HT(3) receptor antagonist and dexamethasone)
Study: 24746177
Drug: Aprepitant add-on
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant add-on therapy in patients taking carboplatin and pemetrexed
Study: 24746177
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic therapy in patients taking carboplatin and pemetrexed
Study: 23236685
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) coated mini implant
Study: 23236685
Drug: Plain mini
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain mini implant (control)
Study: 10206085
Drug: rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 2 mg in the fasting state
Study: 10206085
Drug: rosiglitazone 2
Normalized name: rosiglitazone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 2 mg following a standard high-fat breakfast
Study: 157810
Drug: Intravenous tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tolbutamide
Study: 157810
Drug: Intravenous glibornuride
Normalized name: glibornuride
DrugBank: Glibornuride (DB08962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glibornuride
Study: 19671016
Drug: Antibiotic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic resistance
Study: 31977129
Drug: Antibiotic-resistant genes
Normalized name: Genesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-resistant genes
Study: 31251102
Drug: Honokiol liposome
Normalized name: honokiol
DrugBank: Honokiol (DB19283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honokiol liposome injection (HKLI)
Study: 25590308
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline spray
Study: 18178988
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily for 2 weeks, followed by flexible dose of 10 to 20 mg daily for 6 weeks
Study: 15349784
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (12 g l(‐1) solution, 4 aliquots of 250 ml at 30 min intervals before exercise, additional 150 ml every 15 min during exercise)
Study: 9310273
Drug: Spirapril, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril, 6 mg once daily
Study: 9310273
Drug: Enalapril, 5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 5-20 mg once daily
Study: 8339560
Drug: Cyclosporine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 1% ophthalmic ointment
Study: 3554278
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of compression and O-(beta-hydroxyethyl)-rutosides
Study: 30830164
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical parameters + biomarkers (leptin + high molecular weight adiponectin + VEGF)
Study: 26780387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lenalidomide (15 mg/kg), docetaxel (75 mg/m²), and prednisone (10 mg daily)
Study: 21146655
Drug: 30 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Study: 21146655
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of dual antiplatelet therapy (DAPT) with thienopyridine (clopidogrel or prasugrel) plus aspirin
Study: 21146655
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin after 12 months of open-label thienopyridine treatment
Study: 11976834
Drug: 5-FU with
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU with food (20 mg/m(2), orally)
Study: 11976834
Drug: 5-FU in
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU in fasted state (20 mg/m(2), orally)
Study: 2101962
Drug: Clenbuterol (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenbuterol (0.04 mg, p.o.)
Study: 2101962
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) (50 mg, i.v.) alone
Study: 2101962
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) (50 mg, i.v.) with Clenbuterol (0.04 mg, p.o.)
Study: 26483291
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (3 months, 12 weekly sessions)
Study: 23233719
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily + Temsirolimus 30 mg daily (5 days every 2 weeks)
Study: 9663726
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. after meals for 2 weeks (group LA)
Study: 9663726
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.d. + Amoxycillin 500 mg q.d.s. + Ecabet sodium 1000 mg b.d. after meals for 2 weeks (group LAE)
Study: 2932137
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of nebulized ipratropium bromide after 10 mg salbutamol by nebulizer
Study: 2932137
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg salbutamol (two doses 2 hours apart)
Study: 30891604
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of EV71 vaccine (dose 1) and HepB on day 1 and EV71 vaccine (dose 2) and MenA on day 30 (SI group)
Study: 30891604
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of doses 1 and 2 of EV71 vaccine on days 1 and 30, respectively (SE1 group)
Study: 30891604
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of HepB and MenA on days 1 and 30, respectively (SE2 group)
Study: 26891753
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human G-CSF
Study: 25314773
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of cytarabine (average dose) in Group 2
Study: 25314773
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses (100 mg/m2) in combination with idarubicin (8‐12 mg/m2) and mitoxantrone (10 mg/m2) in Group 1